* First smallpox vaccine granted market authorization in all EU member states * First MVA-BN®-based product approval KVISTGAARD, Denmark, August 7, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has granted marketing authorization for IMVANEX® (MVA-BN) for active immunization against smallpox disease for the general adult population, including people with weakened immune systems (people diagnosed with HIV or atopic dermatitis). The authorization covers all 27 European Union member states and European Economic Area countries Iceland, Liechtenstein and Norway. IMVANEX will be made available for governments to purchase and use in accordance with official national recommendations. "The marketing authorization of IMVANEX marks a significant milestone for our company and our MVA-BN vaccine technology platform, which we have taken from early research through regulatory approval and now serves as the foundation for multiple candidates in our development pipeline," said Anders Hedegaard, President and CEO of Bavarian Nordic. "We are delighted to receive our first regulatory product approval, and we look forward to working with the European governments to address the requirements for their national preparedness plans, focusing on the advantages that IMVANEX brings in terms of safety and administration for people at risk." IMVANEX is the only smallpox vaccine approved through the centralized procedure and available to all EU member states. Known as IMVAMUNE® in the U.S., it has been developed under contracts with the U.S. Government. To-date, Bavarian Nordic has manufactured and delivered 17 million doses of the vaccine to the U.S. Strategic National Stockpile for emergency use in immune compromised individuals, such as people with atopic dermatitis and HIV who are not recommended to receive conventional, replicating smallpox vaccines. IMVANEX has also been supplied to other government stockpiles around the world. Asger Aamund Chairman of the Board Contacts Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 About IMVANEX (MVA-BN) MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a robust and adaptable vaccine platform suitable for addressing a wide variety of infectious diseases, including biological threats. In addition to developing MVA-BN (trade name IMVANEX) as a safer smallpox vaccine essential to protecting the immune- compromised population, Bavarian Nordic has conducted preclinical and clinical studies of recombinant MVA-BN-based vaccines for a variety of infectious diseases and numerous types of cancer. Almost 5,800 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile. An advantage of MVA-BN is the virus' inability to replicate in a vaccinated individual. The replication cycle is blocked at a very late stage, which ensures that new viruses are not generated and released. This means that the virus cannot spread in the vaccinated person and none of the serious side effects normally associated with replicating vaccinia viruses have been seen with MVA- BN. Bavarian Nordic operates its own commercial-scale multi-purpose manufacturing facility in Denmark that is designed for the manufacture of MVA-BN-based and other poxvirus-based vaccines. About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1721716]
Bavarian Nordic Receives European Marketing Authorization
Top 10 Most Recent News Articles
Class Action Alerts: M&A Under Scrutiny
Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...
Continue Reading
Lawsuit Highlights Inaction in School Bus Tragedy
Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...
Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris
Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...
Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD
Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...
Continue Reading
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up
ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...
Continue ReadingBlack Culture Icon: Plastic-Covered Couch Takes Stage
A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...
Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence
Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...
Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest
A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...
Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals
Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...
Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness
Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...
Continue ReadingTop 5 Most Recently Viewed Articles
The Future of AI: Autonomous Agents Set to Transform Industries
Insights into the Autonomous AI and Autonomous Agents Market The Autonomous AI and Autonomous Agents market, valued at USD 7.4 billion in 2023, is set to reach an astounding USD 86.9 billion by 2032. This surge represents a compound annual growth rate (CAGR) of 36.59% throughout the period from 2025 to 2032. The growth is largely influenced by the ongoing integration of...
Continue Reading
Nio Implements Price Reductions to Strengthen Global Market Position
Nio's Strategic Pricing Initiatives to Compete with Rivals Nio Inc. NIO shares have shown an upward trend in premarket trading as the Chinese electric vehicle manufacturer has initiated significant price cuts across its long-range lineup. This strategic move aims to effectively counter the advances made by top competitor Tesla Inc. TSLA, particularly following the launch...
Continue Reading
Korn Ferry CFO Sells $3.7 Million in Stock Amid Positive Growth
Noteworthy Stock Transactions by Korn Ferry's CFO Korn Ferry (NYSE: KFY) recently attracted attention thanks to significant stock transactions carried out by its Executive Vice President and Chief Financial Officer, Robert P. Rozek. Recent filings show that Rozek sold more than $3.7 million in company shares. These transactions took place over two days and indicate his...
Continue Reading
Oerth Bio's Revolutionary Study on PROTACs for Agriculture
Oerth Bio's Revolutionary Advances in Agriculture Oerth Bio has recently published a significant peer-reviewed study in Nature Communications Biology that introduces an exciting development in agricultural science. Their research showcases one of the first applications of PROTAC technology—Proteolysis-Targeting Chimeras—in an agricultural context. This groundbreaking...
Continue Reading
Innovative AI Enhances Recruiting with Immersive Job Previews
Paradox's Groundbreaking Recognition in HR Technology Paradox, a leader in conversational AI for recruitment, has been awarded as a Top HR Product of 2025. This recognition from HR Executive is a testament to the company’s dedication to innovating the hiring process through cutting-edge technology. The Immersive Job Preview product has been acknowledged for its...
Continue Reading